Helping Latino teens and young adults try the Medtronic 780G insulin pump in Spanish and English
Official title: Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative
Run by University of Colorado, Denver · NCT07720388 · Data updated 2026-11-12
A culturally and linguistically tailored onboarding program helps Latino/Hispanic youth with type 1 diabetes start and keep using the Medtronic MiniMed 780G system.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 10 Years to 20 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Status | Recruiting |
| Started | October 2, 2026 |
| Main results expected | July 2027 |
| Study ends | October 2027 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07720388 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Latino/Hispanic youths aged 10–20 with type 1 diabetes who are ready to start using the Medtronic MiniMed 780G system and participate in Spanish or bilingual activities.
✕Probably not a fit
Patients who do not choose to use the 780G system or who cannot commit to the 8-month program may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests whether a Spanish- and culture-tailored onboarding and ongoing support program increases adoption and sustained use of the Medtronic MiniMed 780G insulin pump among Latino/Hispanic youth with type 1 diabetes over eight months. It uses a single-group design to measure how many participants are still using the system at six months, along with HbA1c, time in range, hypoglycemia, and user-reported satisfaction. Participants receive in-person nutrition and pump-start education, plus regular virtual check-ins with native Spanish-speaking staff. The study seeks to determine if language- and culture-adapted onboarding can reduce disparities in technology adoption and improve clinical outcomes.
Why it matters
Potential benefit: If successful, participants could maintain better diabetes control and more consistently use advanced insulin pump technology.
How similar studies have gone: Previous studies show that culturally tailored diabetes education can improve engagement and outcomes in minority populations, but this specific onboarding approach for automated insulin delivery is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 10 - 20 years old * Diagnosis of type 1 diabetes * Self-identify as Latino/Hispanic (determined via self-report and/or electronic health record) * Currently managing diabetes using any regimen, including multiple daily injections (MDI) or any non-Medtronic automated insulin delivery system * Willing to transition to and use the Medtronic MiniMed 780G system for the duration of the study Exclusion Criteria: * Current use of any Medtronic technology * More than 1 episode of diabetic ketoacidosis (DKA) within 12 months of study enrollment * Current pregnancy (self-reported), due to limited safety data for use of the Medtronic MiniMed 780G system during pregnancy * Presence of any significant medical condition that, in the opinion of the investigator, would interfere with study participation or data interpretation * Inability or unwillingness to use the Medtronic MiniMed 780G system for the duration of the study
Where it's running
-
Barbara Davis Center
Aurora, Colorado, United States Recruiting
Study contacts
- Study coordinator: Study Coordinator
- Email: Karen.Hernandez@cuanschutz.edu
- Phone: 303-724-4315
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
Tele-diabetes remote monitoring for kids with type 1 diabetes
This study tests a tele-diabetes remote system that uses WhatsApp alerts to help children and teens manage their type 1 diabetes at home.
-
AHEAD Program to support 16–19-year-olds with type 1 diabetes as they move to adult care
This project will test whether the AHEAD Program helps 16–19-year-olds with type 1 diabetes keep their blood sugar under better control while moving from pediatric to adult care.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.